Riede, O
Seifert, K
Oswald, D
Endmann, A
Hock, C
Winkler, A
Salguero, F J
Schroff, M
Croft, S L
Juhls, C http://orcid.org/0000-0003-1357-4065
Article History
Received: 3 November 2014
Revised: 20 February 2015
Accepted: 27 March 2015
First Online: 30 April 2015
Competing interests
: OR, DO, AE and CJ are employees and MS is Chairman of the Executive Board of Mologen AG. CH is employee of IMGM Laboratories GmbH. AW is employee of LPT GmbH & Co. KG. MOLOGEN AG owns a patent for the MIDGE-Th1 vector (PCT/DE02/03798P74). These affiliations do not alter the authors’ adherence to Gene Therapy policies on sharing data and materials. FJS declares no conflict of interest.